Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E Drolen, Tatyana Feldman, Tarek Haykal, Caroline A Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B Johnson, Ankit Mangla, Christopher Dittus, Praful Ravi, Robert A Baiocchi, Elizabeth Y Chiao, Paul G Rubinstein, Sarvari V Yellapragada, Ann S LaCasce, Guru P Sonpavde, Abdul Rafeh Naqash, Alex F Herrera
BACKGROUND: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL). PATIENTS/METHODS: We retrospectively identified patients with HIV-cHL from the "Cancer Therapy using Checkpoint inhibitors in People with HIV-International (CATCH-IT)" database who received nivolumab or pembrolizumab, alone or in combination with other agents, and reviewed records for demographics, disease characteristics, immune-mediated adverse events (imAEs), and treatment outcomes...
April 5, 2024: Clinical Lymphoma, Myeloma & Leukemia